Charles River Laboratories and PathoQuest are expanding their strategic partnership agreement to provide next-generation sequencing (NGS) services to the biologics industry. As part of the expanded partnership, Charles River intends to make a direct investment in PathoQuest. “Our partnership with PathoQuest is integral to our ability to provide the most sensitive testing methods to our clients…